News
Come meet us
Our latest publications
Find all our latest news, press releases and scientific publications.
First Patient In for the HARMONY 360 study
Ad Scientiam announces a critical milestone with the enrollment of the First Patient In in the HARMONY 360 study
We announce the enrollment of the First Patient In in the HARMONY 360 study, conducted in collaboration with Merck KGaA, Darmstadt, Germany, to explore multimodal remote digital monitoring of generalized Myasthenia Gravis with MyoSense 360.
October 8, 2026
MSCopilot® interim results at EAN 2026
Ad Scientiam unveils positive 1-year interim longitudinal results for MSCopilot® at EAN 2026
At the 12th Congress of the European Academy of Neurology in Geneva, we present the first encouraging 1-year results from our MS-DETECT and MS-FLOWER studies, confirming the reliability of MSCopilot® for long-term monitoring of multiple sclerosis.
June 29, 2026
4 scientific posters at AAN 2026
Ad Scientiam at AAN 2026: 4 scientific posters to anchor digital biomarkers in neurological practice
In Chicago, April 18-22, 2026, Ad Scientiam presented 4 scientific posters at the American Academy of Neurology, covering MSCopilot® in MS and ME&MG™ in generalized autoimmune myasthenia.
April 18, 2026
Ad Scientiam expands to the US
Ad Scientiam officially establishes presence in the United States
We announce a decisive step in our international development: the opening of our American subsidiary and the registration of MSCopilot® with the FDA.
April 16, 2026
MuCopilot® at JSM 2025
JSM 2025 — MuCopilot®: optimizing cystic fibrosis monitoring through digital biomarkers
At the Cystic Fibrosis Scientific Days 2025, we presented MuCopilot®, our home monitoring tool based on digital biomarkers measured via smartphone.
March 9, 2026
MSCopilot® biomarkers and clinical assessments
MSCopilot® biomarkers reflect traditional clinical assessments
In Dubai in December 2025, we presented MS-DETECT data on the correlation between MSCopilot® digital biomarkers and traditional clinical assessments.
December 5, 2025
